Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 3/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.41 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL29248949 | 0.95 | MCL1 (0.41) | MCL1MRGPRX4DHODHP2RX3PTGER4 | |
| SCHEMBL24257685 | 0.91 | MAOB (0.47) | MRGPRX4DHODHPTGER4MAOB | |
| SCHEMBL30453121 | 0.91 | MAOB (0.47) | MRGPRX4DHODHPTGER4MAOB | |
| SCHEMBL24257668 | 0.88 | FFAR1 (0.43) | MRGPRX4DHODHPTGER4FFAR1FFAR4 | |
| SCHEMBL30454075 | 0.86 | PTGER1 (0.47) | MRGPRX4PTGER1 | |
| SCHEMBL30453291 | 0.86 | C5AR1 (0.43) | MRGPRX4DHODHNR4A2FFAR1PTGER1 | |
| SCHEMBL24257669 | 0.86 | C5AR1 (0.43) | MRGPRX4DHODHNR4A2FFAR1PTGER1 | |
| SCHEMBL24257585 | 0.86 | PTGER1 (0.47) | MRGPRX4PTGER1 | |
| Glycine SCHEMBL30546864 | 0.85 | JAK2 (0.44) | FFAR1FFAR4 | |
| SCHEMBL24257621 | 0.84 | MCL1 (0.44) | MCL1MRGPRX4DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| CN-116670131-A | PHD inhibitor compounds, compositions, and methods of use | 阿克比治疗有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4196466-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | MCL1 2389/4885MRGPRX4 3994/4885DHODH 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.